Hamlet Pharma

Hamlet Pharma & SelectImmune are inviting you to a digital investors’ meeting via Zoom, on Monday and Tuesday, April 3^rd and April 4^th of at 12.00 CET, for dialogue about the merger. We welcome existing owners, other investors and interested parties to join. The meeting participants will be informed of the company developments and will be invited to ask questions. These may be asked online during the meeting or be sent via e-mail to the addresses listed below. The meeting will be held in Swedish with presentation slides  in English. Please use these links to participate:

Monday 3^rd of April at 12 CET:

https://us06web.zoom.us/j/86082931807?pwd=ekViYnFHTTUxYTRIZHQ2RVd5NEVYdz09

Tuesday 4th of April at 12 CET:

https://us06web.zoom.us/j/89697967748?pwd=NStwRUxGZ3hmdGE4elJsbXRkbmE3Zz09

For more information, contact

Catharina Svanborg

Phone +46-709-426549

Jan Zetterberg

Phone: +46-705-544300

info@hamletpharma.com

About HAMLET Pharma

HAMLET Pharma, listed on Spotlight, develops drugs based on the unique tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in breast milk. Development focuses primarily on drugs, for the treatment and prevention of cancer. HAMLET kills tumour cells and has proven safe in proof-of-concept studies in animal models. Alpha1H is the synthetic variant of HAMLET, which has enabled development of the agent for clinical trials. Alpha1H kills different types of tumour cells and has demonstrated therapeutic effects on bladder cancer in animal models. Hamlet Pharma has one ongoing Phase I/II clinical trial with Alpha1H in patients with bladder cancer, a costly form of cancer that is difficult to treat, and intends to expand its activities into other types of cancer. The first results from the ongoing clinical Phase I/II study shows no side effects of Alpha1H, indicating that the treatment is safe and well tolerated. Alpha1H also demonstrated clinical efficacy compared with patients who received placebo. In addition, Hamlet Pharma develops BAMLET, which is a molecular complex formed by bovine α-lactalbumin and oleic acid. Data from animal models suggest that local BAMLET treatment may be effective against colon cancer.